| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 39,072 | 37,599 | ||
| Marketable securities, available-for-sale | 239,219 | 249,041 | ||
| Marketable equity securities | 2,406 | 16,791 | ||
| Contracts receivable | 0 | 0 | ||
| Prepaid expenses and other current assets | 7,605 | 8,165 | ||
| Total current assets | 288,302 | 311,596 | ||
| Property and equipment, net | 2,927 | 3,087 | ||
| Operating leaseright-of-useassets | 30,188 | 31,175 | ||
| Prepaid expenses and other assets | 3,206 | 3,222 | ||
| Restricted cash | 2,627 | 2,627 | ||
| Total assets | 327,250 | 351,707 | ||
| Accounts payable | 7,031 | 3,719 | ||
| Accrued expenses | 30,137 | 35,303 | ||
| Total current liabilities | 37,168 | 39,022 | ||
| Long-term lease liability | 36,708 | 37,690 | ||
| Other long-term liabilities | 500 | 500 | ||
| Total liabilities | 74,376 | 77,212 | ||
| Common stock, 0.001 par value 250,000,000 shares authorized 72,245,529 and 71,282,400 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 72 | 72 | ||
| Additional paid-in capital | 1,408,855 | 1,403,912 | ||
| Accumulated other comprehensive income | 186 | 59 | ||
| Accumulated deficit | -1,156,239 | -1,129,548 | ||
| Total stockholders equity | 252,874 | 274,495 | ||
| Total liabilities and stockholders equity | 327,250 | 351,707 | ||
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)